| Citation: |
TONG Gangling, CHENG Boran, CHEN Xiaoqiu, SHEN Donglan, PENG An, WANG Shubin. Comparison of Clinical Effect Between mFOLFOX6 and FOLFIRI Regimen as Alternately First-and Second-line Therapy on Advanced Gastric Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2017, 44(7): 489-492. DOI: 10.3971/j.issn.1000-8578.2017.17.0077
|
To observe and compare the efficacy and adverse reactions between mFOLFOX6 and FOLFIRI regimen as alternately first-and second-line chemotherapy on the patients with advanced gastric cancer(AGC).
A total of 62 AGC patients were divided into two groups: Control group, n=32, mFOLFOX6 regimen as the first-line treatment, FOLFIRI regimen as the second-line treatment on 25 patients after disease progression; Observation group, n=30, FOLFIRI regimen as the first-line therapy, mFOLFOX6 regimen as the second-line treatment on 25 patients after disease progression. The efficacy and adverse effects were evaluated.
The overall response rates of first-, second-line therapy between control group and observation group were 37.5%, 24.0% and 40.0%, 16.0%, respectively(P=0.801, P=0.662); the median progression-free survival were (5.0±0.25), (2.0±0.36) and (6.0±0.81), (2.0±0.27) months, respectively, with no statistically significant difference (P=0.178, P=0.803); the median overall survival were (10.0±1.06) and (11.0±1.17) months in two groups(P=0.500). The most common toxicities in both groups were myelosuppression, gastrointestinal tract reaction and neurotoxicity. Control group had much higher neurotoxicity than observation group, nevertheless, the rate of diarrhea in observation group was higher than that in control group in first-line treatment.
mFOLFOX6 and FOLFIRI regimen have equal effect as alternately first-and second-line treatment on AGC patients, and both can prolong survival with low toxicity.
| [1] |
符涛, 季加孚.胃癌诊疗的热点和问题[J].中国肿瘤临床, 2016, 43(1):1-5. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL201601005.htm
Fu T, Ji JF. The foci and problems in diagnosis and treatment of gastric cancer[J]. Zhongguo Zhong Liu Lin Chuang, 2016, 43(1): 1-5. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL201601005.htm
|
| [2] |
Sawaki A, Ohashi Y, Omuro Y, et al. Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer(ToGA) study[J]. Gastric Cancer, 2012, 15(3): 313-22. doi: 10.1007/s10120-011-0118-1
|
| [3] |
Hacibekiroglu I, Kodaz H, Erdogan B, et al. Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer[J]. Mol Clin Oncol, 2015, 3(5): 1160-4. https://www.spandidos-publications.com/mco/3/5/1160
|
| [4] |
Sendur MA, Ozdemir N, Özatlı T, et al. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen[J]. Med Oncol, 2014, 31(9): 153. doi: 10.1007/s12032-014-0153-y
|
| [5] |
李跃军, 卓德斌. SOX方案对比FOLFOX4方案治疗进展期胃癌的临床观察[J].肿瘤研究与临床, 2014, 26(1): 42-4. http://www.cnki.com.cn/Article/CJFDTOTAL-YYXK201423151.htm
Li YJ, Zhuo DB. Comparison between the effect of SOX regimen and FOLFOX4 regimen for advanced gastric cancer[J]. Zhong Liu Yan Jiu Yu Lin Chuang, 2014, 26(1): 42-4. http://www.cnki.com.cn/Article/CJFDTOTAL-YYXK201423151.htm
|
| [6] |
徐智, 陈怡, 陈锦飞. 3种常用联合化疗方案一线治疗晚期胃癌的疗效和安全性比较[J].实用老年医学, 2014, 28(12): 1003-6. http://www.cnki.com.cn/Article/CJFDTOTAL-SYLA201412013.htm
Xu Z, Chen Y, Chen JF. Analysis of efficacy and safety of three commomly used combination chemoregimens in treatment of advanced gastric adenocarcinoma[J]. Shi Yong Lao Nian Yi Xue, 2014, 28(12): 1003-6. http://www.cnki.com.cn/Article/CJFDTOTAL-SYLA201412013.htm
|
| [7] |
Tsuji K, Yasui H, Onozawa Y, et al. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study[J]. Jpn J Clin Oncol, 2012, 42(8): 686-90. doi: 10.1093/jjco/hys084
|
| [8] |
Kwon HJ, Park MI, Park SJ, et al. Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer[J]. Korean J Gastroenterol, 2015, 66(1): 10-6. doi: 10.4166/kjg.2015.66.1.10
|
| [9] |
于立江, 潘月琴, 马德, 等.紫杉醇联合FOLFOX方案在晚期胃癌二线化疗中的应用[J].肿瘤基础与临床, 2013, 26(6): 535-6. http://www.cnki.com.cn/Article/CJFDTOTAL-HLZL201306027.htm
Yu LJ, Pan YQ, Ma D, et al. Paclitaxel combined with FOLFOX regimen in second-line chemotherapy for advanced gastric cancer[J]. Zhong Liu Ji Chu Yu Lin Chuang, 2013, 26(6): 535-6. http://www.cnki.com.cn/Article/CJFDTOTAL-HLZL201306027.htm
|
| [10] |
乐薇, 项晓军, 张凌, 等.改良FOLFIRI方案二线治疗老年晚期胃癌患者的临床观察[J].实用肿瘤杂志, 2013, 28(2): 200-3. http://www.cnki.com.cn/Article/CJFDTOTAL-SYZZ201302032.htm
Le W, Xiang XJ, Zhang L, et al. Clinical observation of modified FOLFIRI regimen as second-line chemotherapy for elderly patients with advanced gastric cancer[J]. Shi Yong Zhong Liu Za Zhi, 2013, 28(2): 200-3. http://www.cnki.com.cn/Article/CJFDTOTAL-SYZZ201302032.htm
|
| [11] |
Xu HB, Huang F, Su R, et al. Capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOXs) in advanced gastric cancer: Meta-analysis of randomized controlled trials[J]. Eur J Clin Pharmacol, 2015, 71(5): 589-601. doi: 10.1007/s00228-015-1828-9
|
| [12] |
Bajetta E, Floriani I, Di Bartolomeo M, et al. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resectedgastric cancer[J]. Ann Oncol, 2014, 25(7): 1373-8. doi: 10.1093/annonc/mdu146
|
| [1] | WANG Ya'nan, LU Wenping, MEI Heting, CUI Yongjia, ZHUO Zhili. Risk of Recurrence or Metastasis of Breast Cancer by LNG-IUS: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2022, 49(8): 786-791. DOI: 10.3971/j.issn.1000-8578.2022.21.1536 |
| [2] | XIA Lin, YU Guozheng, TANG Jing. Diagnostic Value of Circular RNAs for Colorectal Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2021, 48(9): 864-870. DOI: 10.3971/j.issn.1000-8578.2021.21.0069 |
| [3] | LIANG Tong, LIU Huajie, DA Mingxu. Metabolic Syndrome and Risk of Gastric Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2021, 48(3): 268-273. DOI: 10.3971/j.issn.1000-8578.2021.20.0957 |
| [4] | SHAO Lihua, ZHANG Qiuning, LUO Hongtao, YANG Zhen, LIU Ruifeng, TIAN Jinhui, LI Zheng, WANG Xiaohu, YANG Kehu. Carbonions and Proton Therapy for Hepatocellular Carcinoma: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2020, 47(5): 358-366. DOI: 10.3971/j.issn.1000-8578.2020.19.1158 |
| [5] | JIAN Yaowen, WANG Lei, Liu Ye, HE Mingyan, RANG Weiqing. A Meta-analysis of Dietary Vitamin Consumption and Risk of Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2020, 47(2): 108-111. DOI: 10.3971/j.issn.1000-8578.2020.19.0007 |
| [6] | KUANG Yuhui, CHEN Xinju, XU Fangbiao. Meta-analysis of Efficacy and Safety of Jinlong Capsule Combined with Chemoradiotherapy on Liver Metastases[J]. Cancer Research on Prevention and Treatment, 2020, 47(1): 63-69. DOI: 10.3971/j.issn.1000-8578.2020.19.0619 |
| [7] | CAO Lingzhi, XIE Jianping, PENG Xiaodong, WEN Huling, LI Suping, YANG Yaowu. Association of Iodine Intake and Iodine-enriched Food with Risk of Thyroid Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2016, 43(7): 616-622. DOI: 10.3971/j.issn.1000-8578.2016.07.015 |
| [8] | LIU Min, SONG Yang, YANG Fuguo. Effect of Food Intake on Risk of Rectal Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2014, 41(12): 1343-1347. DOI: 10.3971/j.issn.1000-8578.2014.12.020 |
| [9] | Ma Jun, Nie Shengnan, Shi Benling, Zuo Wenshu. Meta Analysis on Relationship between Soyfood and Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2012, 39(02): 218-221. DOI: 10.3971/j.issn.1000-8578.2012.02.025 |
| [10] | QIU Yue-feng, CAI Lin. Meta-analysis on Relationship between Body Mass Index and Lung Cancer Risk[J]. Cancer Research on Prevention and Treatment, 2010, 37(02): 218-222. DOI: 10.3971/j.issn.1000-8578.2010.02.025 |
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: